Skip to content

Study · Not a test of the peptide alone · 2001

5 results

[Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin].

Parneix I, Emperaire JC, Ruffie A, Parneix P

Gynecologie, obstetrique & fertilite1 Feb 2001Cited by 16 (Europe PMC)

PMID11262842 (opens in a new tab)DOI10.1016/s1297-9589(00)00064-3 (opens in a new tab)PepBankPUB-11262842
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In treatment cycles using GnRH agonist regimens including triptorelin, ovulation occurred in all reported regimen groups.

    In plain wordsIn treatment cycles, GnRH agonist regimens including triptorelin triggered ovulation in all reported regimen groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableOvulation
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Ovulation with supraphysiologic elevation of both FSH and LH was achieved in the 13 GnRHa groups.
    2 context sentences
    Summary · context
    Thirteen different regimens of GnRH-a administration were used to trigger ovulation using different dosages and either one, two or three administrations: triptorelin, buserelin spray, buserelin subcutaneously, leuprolide and nafarelin in 231 treatment cycles.
    Summary · context
    Pregnancy rate and luteal phase duration were compared with those of a control group for whom ovulation was triggered with hCG.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In treatment cycles using GnRH agonist regimens including triptorelin, ovulation involved supraphysiologic FSH elevation.

    In plain wordsIn treatment cycles, GnRH agonist regimens including triptorelin produced FSH elevations above normal physiological levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFSH elevation
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Ovulation with supraphysiologic elevation of both FSH and LH was achieved in the 13 GnRHa groups.
    2 context sentences
    Summary · context
    Thirteen different regimens of GnRH-a administration were used to trigger ovulation using different dosages and either one, two or three administrations: triptorelin, buserelin spray, buserelin subcutaneously, leuprolide and nafarelin in 231 treatment cycles.
    Summary · context
    Pregnancy rate and luteal phase duration were compared with those of a control group for whom ovulation was triggered with hCG.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In treatment cycles using GnRH agonist regimens including triptorelin, ovulation involved supraphysiologic LH elevation.

    In plain wordsIn treatment cycles, GnRH agonist regimens including triptorelin produced LH elevations above normal physiological levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseLH elevation
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Ovulation with supraphysiologic elevation of both FSH and LH was achieved in the 13 GnRHa groups.
    2 context sentences
    Summary · context
    Thirteen different regimens of GnRH-a administration were used to trigger ovulation using different dosages and either one, two or three administrations: triptorelin, buserelin spray, buserelin subcutaneously, leuprolide and nafarelin in 231 treatment cycles.
    Summary · context
    Pregnancy rate and luteal phase duration were compared with those of a control group for whom ovulation was triggered with hCG.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In treatment cycles, pregnancy rates did not differ significantly between GnRH agonist groups including triptorelin.

    In plain wordsIn treatment cycles, pregnancy rates did not differ significantly between GnRH agonist groups including triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePregnancy rate between agonists
    Study

    n: not reported in source

    Comparator
    Other GnRH agonists
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Pregnancy rates were not statistically different between the agonist groups or in comparison with the hCG group.
    2 context sentences
    Summary · context
    Thirteen different regimens of GnRH-a administration were used to trigger ovulation using different dosages and either one, two or three administrations: triptorelin, buserelin spray, buserelin subcutaneously, leuprolide and nafarelin in 231 treatment cycles.
    Summary · context
    Pregnancy rate and luteal phase duration were compared with those of a control group for whom ovulation was triggered with hCG.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In treatment cycles, pooled GnRH agonist pregnancy rates did not differ significantly from hCG.

    In plain wordsIn treatment cycles, pooled GnRH agonist pregnancy rates did not differ significantly from hCG.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePregnancy rate versus hCG
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Pregnancy rates were not statistically different between the agonist groups or in comparison with the hCG group.
    2 context sentences
    Summary · context
    Thirteen different regimens of GnRH-a administration were used to trigger ovulation using different dosages and either one, two or three administrations: triptorelin, buserelin spray, buserelin subcutaneously, leuprolide and nafarelin in 231 treatment cycles.
    Summary · context
    Pregnancy rate and luteal phase duration were compared with those of a control group for whom ovulation was triggered with hCG.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.